Inclusion | Criteria |
---|---|
Diagnosis Type 2 Diabetes | ≥ 6 months prior to enrollment |
Age | 30–80 years |
Hba1c at screening | ≤ 10 |
Male or Female | Female of child bearing age must use definitive contraceptive therapy |
Exclusion | |
Taken Prescription sympathomimetic | Taken seven days prior to screening |
Drugs not permitted during study | Ergot alkaloid derivatives, or anti-migrane medications |
History of alcoholism or drug abuse | Within 3 years of study entry |
Donation of blood | 30 days prior to study entry |
Has received any experimental drug or used an experimental device | Within 30 days of study entry |
Pregnant or lactating women | |
Known hypersensitivity to any of the formulation components | |
Subjects with clinically significant major organ system disease: | |
• seizure disorder, | |
• significant gastroparesis or orthostatic hypotension (autonomic neuropathy), | |
• cerebrovascular accident in the previous 6 months, | |
• uncontrolled hypertension (systolic BP >160 or diastolic BP > 100 at screening) | |
• coronary artery bypass graft or coronary angioplasty in the previous 3 months, myocardial infarction in the previous 6 months, or unstable angina pectoris (chest pain at rest, worsening chest pain, or admission to the ER or hospital for chest pain) within the previous 3 months, | |
• congestive heart failure defined by NYHA as Class III or IV | |
• clinical nephrotic syndrome, or renal impairment with a serum creatinine > 1.4 mg/dl if female receiving treatment with metformin, > 1.5 mg/dl if male receiving treatment with metformin, and > 1.6 mg/dl in not on metformin, | |
• impaired liver function, including having AST or ALT greater than three times the upper limit of normal, | |
• active infection (e.g., HIV, hepatitis), or a history of severe infection during the 30 days prior to screening, | |
• major surgical operation during the 30 days prior to screening, | |
• cancer, other than non-melanoma skin or non metastatic prostate cancer within the past 5 years | |
• Any concurrent illness, other than diabetes mellitus, not controlled by a stable therapeutic regimen. | |
• Working rotating, varying or night shifts | |
• Patients taking unapproved herbal supplements that may be associated with a risk of cardiovascular events (such as ephedra, yohimbe etc) | |
• Patients who have started therapy with an erectile dysfunction drug within 2 weeks prior to screening; patients may not begin treatment with an erectile dysfunction drug during the study period; patients previously taking erectile dysfunction drugs should do so only under medical supervision. | |
• Subjects with circumstances or abnormalities (e.g., blindness or a history of non-compliance) that would interfere with the interpretation of safety or efficacy data or completion of the study. |